Markets & Regulations

Althea announces first phase of ADC offerings

Althea announces first phase of ADC offerings

By Melissa Fassbender

Althea is expanding its biological drug product manufacturing operations to include highly active materials, such as Antibody Drug Conjugates (ADCs).

Capping the price of reference drugs 'is detrimental' to biosimilars and generics, says the EGA

EGA: let originators charge more in Spain… to boost biosimilars

By Fiona BARRY

The European Generic and Biosimilar Medicines Association (EGA) and the Spanish Generic Medicines Association (AESEG) today revealed plans to remove market barriers to biosimilars and small molecule generics and create thousands of jobs.

Follow us